MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause
- 1 February 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (2) , R79-R91
Abstract
Postmenopausal hyperandrogenism is a state of relative or absolute androgen excess originating from either the adrenals and/or the ovaries, clinically manifested as the appearance and/or increase in terminal hair growth or the development of symptoms/signs of virilization. In either settings, physicians need to evaluate such patients and exclude the presence of the relatively rare but potentially life-threatening underlying tumorous causes, particularly adrenal androgen-secreting tumors. It has been suggested that the rapidity of onset along with severity of symptom and the degree of androgen excess followed by relevant imaging studies may suffice to identify the source of excessive androgen secretion. However, up to date, there is no consensus regarding specific clinical and hormonal indices and/or imaging modalities required for diagnostic certainty. This is particularly relevant as the aging population is increasing and more cases of postmenopausal women with clinical/biochemical evidence of hyperandrogenism may become apparent. Furthermore, the long-term sequels of nontumorous hyperandrogenism in postmenopausal women in respect to cardiovascular morbidity and mortality still remain unsettled. This review delineates the etiology and pathophysiology of relative and absolute androgen excess in postmenopausal women. Also, it attempts to unravel distinctive clinical features along with specific hormonal cut-off levels and/or appropriate imaging modalities for the facilitation of the differential diagnosis and the identification of potential long-term sequels.Keywords
This publication has 104 references indexed in Scilit:
- Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literatureWorld Journal of Surgical Oncology, 2013
- Age-Specific Reference Ranges for Serum Testosterone and Androstenedione Concentrations in Women Measured by Liquid Chromatography-Tandem Mass SpectrometryThe Journal of Clinical Endocrinology & Metabolism, 2012
- Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studiesBritish Journal of Cancer, 2011
- Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 UpdateJACC, 2011
- Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast CancersJNCI: Journal of the National Cancer Institute, 2011
- Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- Criteria for Polycystic Ovarian Morphology in Polycystic Ovary Syndrome as a Function of AgeThe Journal of Clinical Endocrinology & Metabolism, 2009
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus StatementThe Journal of Clinical Endocrinology & Metabolism, 2008
- Withdrawn: Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome EvaluationThe Journal of Clinical Endocrinology & Metabolism, 2008
- Profile and outcome of pure androgen-secreting adrenal tumors in women: Experience of 21 casesSurgery, 2004